420 related articles for article (PubMed ID: 31701486)
1. Basics to advances in nanotherapy of colorectal cancer.
Tiwari A; Saraf S; Jain A; Panda PK; Verma A; Jain SK
Drug Deliv Transl Res; 2020 Apr; 10(2):319-338. PubMed ID: 31701486
[TBL] [Abstract][Full Text] [Related]
2. Last Advances in Nanocarriers-Based Drug Delivery Systems for Colorectal Cancer.
Rama AR; Jimenez-Lopez J; Cabeza L; Jimenez-Luna C; Leiva MC; Perazzoli G; Hernandez R; Zafra I; Ortiz R; Melguizo C; Prados J
Curr Drug Deliv; 2016; 13(6):830-8. PubMed ID: 26634791
[TBL] [Abstract][Full Text] [Related]
3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
4. Micelles as potential drug delivery systems for colorectal cancer treatment.
Fatfat Z; Fatfat M; Gali-Muhtasib H
World J Gastroenterol; 2022 Jul; 28(25):2867-2880. PubMed ID: 35978871
[TBL] [Abstract][Full Text] [Related]
5. Liposome technologies towards colorectal cancer therapeutics.
Sang R; Stratton B; Engel A; Deng W
Acta Biomater; 2021 Jun; 127():24-40. PubMed ID: 33812076
[TBL] [Abstract][Full Text] [Related]
6. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
7. Management of Colorectal Cancer Using Nanocarriers-based Drug Delivery for Herbal Bioactives: Current and Emerging Approaches.
Deshmukh R; Prajapati M; Harwansh RK
Curr Pharm Biotechnol; 2024; 25(5):599-622. PubMed ID: 38807329
[TBL] [Abstract][Full Text] [Related]
8. Insight to drug delivery aspects for colorectal cancer.
Gulbake A; Jain A; Jain A; Jain A; Jain SK
World J Gastroenterol; 2016 Jan; 22(2):582-99. PubMed ID: 26811609
[TBL] [Abstract][Full Text] [Related]
9. Magnetically driven drug delivery systems improving targeted immunotherapy for colon-rectal cancer.
Grifantini R; Taranta M; Gherardini L; Naldi I; Parri M; Grandi A; Giannetti A; Tombelli S; Lucarini G; Ricotti L; Campagnoli S; De Camilli E; Pelosi G; Baldini F; Menciassi A; Viale G; Pileri P; Cinti C
J Control Release; 2018 Jun; 280():76-86. PubMed ID: 29733876
[TBL] [Abstract][Full Text] [Related]
10. Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer.
Sen K; Banerjee S; Mandal M
Colloids Surf B Biointerfaces; 2019 Aug; 180():9-22. PubMed ID: 31015105
[TBL] [Abstract][Full Text] [Related]
11. Polymeric nanocarriers: A promising tool for early diagnosis and efficient treatment of colorectal cancer.
Haider M; Zaki KZ; El Hamshary MR; Hussain Z; Orive G; Ibrahim HO
J Adv Res; 2022 Jul; 39():237-255. PubMed ID: 35777911
[TBL] [Abstract][Full Text] [Related]
12. Recent progress of targeted nanocarriers in diagnostic, therapeutic, and theranostic applications in colorectal cancer.
Choudhury H; Pandey M; Saravanan V; Mun ATY; Bhattamisra SK; Parikh A; Garg S; Gorain B
Biomater Adv; 2023 Oct; 153():213556. PubMed ID: 37478770
[TBL] [Abstract][Full Text] [Related]
13. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.
Gbenedio OM; Bonnans C; Grun D; Wang CY; Hatch AJ; Mahoney MR; Barras D; Matli M; Miao Y; Garcia KC; Tejpar S; Delorenzi M; Venook AP; Nixon AB; Warren RS; Roose JP; Depeille P
JCI Insight; 2019 Jun; 5(15):. PubMed ID: 31237864
[TBL] [Abstract][Full Text] [Related]
14. A shift in focus towards precision oncology, driven by revolutionary nanodiagnostics; revealing mysterious pathways in colorectal carcinogenesis.
Sharma S; Bhattacharya S; Joshi K; Singh S
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16157-16177. PubMed ID: 37650995
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and clinical monitoring strategies for immune checkpoint inhibitors and targeted cytokine immunotherapy for locally advanced and metastatic colorectal cancer.
Bess SN; Greening GJ; Muldoon TJ
Cytokine Growth Factor Rev; 2019 Oct; 49():1-9. PubMed ID: 31679887
[TBL] [Abstract][Full Text] [Related]
16. Engineered liposomes mediated approach for targeted colorectal cancer drug Delivery: A review.
Shazleen Ibrahim I; Starlin Chellathurai M; Mahmood S; Hakim Azmi A; Harun N; Ulul Ilmie Ahmad Nazri M; Muzamir Mahat M; Mohamed Sofian Z
Int J Pharm; 2024 Feb; 651():123735. PubMed ID: 38142874
[TBL] [Abstract][Full Text] [Related]
17. Development of EGFR-targeted evodiamine nanoparticles for the treatment of colorectal cancer.
Li C; Cai G; Song D; Gao R; Teng P; Zhou L; Ji Q; Sui H; Cai J; Li Q; Wang Y
Biomater Sci; 2019 Aug; 7(9):3627-3639. PubMed ID: 31328737
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs as Therapeutic Targets and Colorectal Cancer Therapeutics.
Yamamoto H; Mori M
Adv Exp Med Biol; 2016; 937():239-47. PubMed ID: 27573904
[TBL] [Abstract][Full Text] [Related]
19. Precision medicine for metastatic colorectal cancer: an evolving era.
Guler I; Askan G; Klostergaard J; Sahin IH
Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):919-931. PubMed ID: 31475851
[No Abstract] [Full Text] [Related]
20. Triumph against cancer: invading colorectal cancer with nanotechnology.
Vinchhi P; Patel MM
Expert Opin Drug Deliv; 2021 Sep; 18(9):1169-1192. PubMed ID: 33567909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
